Cryoprobe with Integral Agent Delivery Device
A probe for use in a cryosurgical system has an integral device for delivering a treatment agent. A representative delivery device can take on a variety of forms, including a lumen located in an outer retractable sheath surrounding the cryoprobe tip, a channel attached to the side of the cryoprobe tip, a channel inside the cryoprobe tip, or a capsule located at the distal end of the cryoprobe tip. The delivery device is sealed to prevent air from being introduced into the system and is provided with a puncture member to break the seal and release the treatment agent as desired by a medical professional.
1 . A probe for use in a cryosurgical procedure comprising:
a tip conFIG.d to freeze selected tissue during a cryosurgical procedure;
an integral delivery device located proximate the tip, the integral delivery device retaining a treatment agent therein; and
a puncture member for releasing the treatment agent from the integral delivery device.
2 . The probe of claim 1 , wherein the integral delivery device comprises a delivery lumen extending to a sealed end on the tip and wherein the puncture member pierces a seal on the sealed end to release the treatment agent.
3 . The probe of claim 2 , wherein the delivery lumen is integrally formed with the tip.
4 . The probe of claim 2 , wherein the delivery lumen is adjacent a capillary tube and wherein the delivery lumen is fluidly connected to a first access port for receiving the treatment agent and the capillary tube is fluidly connected to a second access port for receiving a high pressure refrigerant.
5 . The probe of claim 1 , wherein the integral delivery device comprises a capsule member attached to the tip and wherein the puncture member ruptures the capsule member to release the treatment agent.
6 . The probe of claim 5 , wherein the puncture member comprises a sheath positioned over capsule member such that withdrawal of the sheath ruptures the capsule member.
7 . The probe of claim 1 , wherein the treatment agent comprises a cryodestructive agent selected from the group consisting of: water, ethanol, glycol, TNF-α, metallic nanoparticles, arsenic trioxide, DMXAA, a pH lowering agent, a chemotherapy agent, ERK inhibitors, a mitochondrial agent, sodium chloride, and AFP.
8 . The probe of claim 1 , wherein the treatment agent comprises a cryoprotective agent selected from the group consisting of: glycerol, propylene, glycol, DMSA, DMSO, AFP, glucose, VM3, and VEG.
9 . The probe of claim 1 , wherein the integral delivery device comprises a plurality of integral delivery devices for retaining a plurality of treatment agents therein.
10 . A method of performing cryosurgery, comprising:
providing a cryoprobe having a cryoprobe tip and an integral delivery device, the integral delivery device sealably retaining a treatment agent;
positioning the cyropobe tip proximate a treatment site; and
releasing the treatment agent from the integral delivery device.
11 . The method of claim 10 , wherein releasing the treatment agent comprises puncturing a seal on the integral delivery device with a puncture member.
12 . The method of claim 10 , wherein releasing the treatment agent comprises rupturing the integral delivery device by withdrawing a sheath from over the integral delivery device.
13 . The method of claim 10 , further comprising:
enhancing the freezing of tissue at the treatment site by releasing a cryodestructive treatment agent from the integral delivery device.
14 . The method of claim 10 , further comprising:
performing a cryosurgical treatment at the treatment site.
15 . The method of claim 14 , wherein the cryosurgical treatment comprises a prostate cancer cryosurgical treatment.
16 . The method of claim 14 , further comprising:
removing the treatment agent from the treatment site with the integral delivery device.
17 . The method of claim 10 , wherein the integral delivery device comprises a first integral delivery device and a second integral delivery device and wherein releasing the treatment agent from the integral delivery device comprises releasing a first treatment agent from the first integral delivery device and releasing a second treatment agent from the second integral delivery device.